10 Best IPO Stocks To Buy Heading into 2025

7. Acelyrin Inc. (NASDAQ:SLRN)

Average Upside Potential: 101.01%

Number of Hedge Fund Holders: 23

Acelyrin Inc. (NASDAQ:SLRN) is a clinical biopharma company that focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. It is dedicated to advancing innovative treatments that address unmet medical needs and improve the lives of patients.

In Q2 2024, the company reported positive Phase 3 results for izokibep in hidradenitis suppurativa (HS), achieving the HiSCR75 primary endpoint and strong response rates in HiSCR90 and HiSCR100 within 12 weeks. Preliminary data from two-thirds of participants show continued improvement through week 16. This followed the earlier positive Phase 2b/3 results in psoriatic arthritis (PsA), reinforcing izokibep’s potential across multiple indications.

It will be completing ongoing trials for izokibep in HS and PsA but not starting new trials in these areas. The Phase 2b/3 trial in uveitis will continue, with top-line data expected in Q4 2024 and an additional Phase 3 trial planned if results are favorable. Acelyrin Inc. (NASDAQ:SLRN) also decided to discontinue the development of SLRN-517, its early anti-c-KIT program, which necessitated a 33% workforce reduction.

Lonigutamab is being developed as a subcutaneous treatment for thyroid eye disease (TED), an autoimmune disorder affecting over 100,000 patients in the US. It targets the IGF-1 receptor, providing rapid and durable disease-modifying effects. Acelyrin Inc. (NASDAQ:SLRN) completed the Phase 1 proof-of-concept trial and is now starting a dose-ranging Phase 2 trial to establish an optimal dosing regimen for the upcoming Phase 3 program.

This patient-centric approach aims to address the unmet needs of TED patients while balancing benefit-risk to define effective dosing. All of these events position the company well for growth.